Program
Antibody-drug Conjugate GSK5533524
In GlaxoSmithKline’s pipeline, ADC targeting MUC-16
. Its studies are mostly in Neoplasms, led by GlaxoSmithKline.
Furthest: phase 1, since Feb 23, 20261 company-led study, 1 open or runningNext primary completion: Feb 6, 2029 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 11 open or running | phase 1since Feb 23, 2026 | Feb 23, 2026 | Feb 6, 2029phase 1 · NCT07438782 |
- Named in GlaxoSmithKline’s own pipeline as
GSK5533524
, phase 1, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 23, 2026First study: phase 1 study in NeoplasmsFirst studyNCT07438782 · 97 planned · United States, Canada, Denmark and more
Ahead
- Feb 6, 2029Primary completion: phase 1 study in NeoplasmsNCT07438782
TargetBeta
“ADC targeting MUC-16”the company's pipeline, read by Claude · source
Other programs on MUC16
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| HWK-016, MUCIN-16-targeted ADCrule | whitehawk-therapeutics-inc | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07438782Neoplasms · United States, Canada, Denmark and more | 1 | Recruiting | Feb 6, 2029 | 97 |
How it is read
Names in the registry
- “GSK5533524”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.